EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy

The introduction of druggable targets has significantly improved the outcomes of non-small cell lung cancer patients (NSCLC). EML4-ALK translocation represents 4–6% of the druggable alterations in NSCLC. With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first...

Descripción completa

Detalles Bibliográficos
Autores principales: Reclusa, Pablo, Laes, Jean-François, Malapelle, Umberto, Valentino, Anna, Rocco, Danilo, Gil-Bazo, Ignacio, Rolfo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798325/
https://www.ncbi.nlm.nih.gov/pubmed/35117067
http://dx.doi.org/10.21037/tcr.2018.11.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798325/
https://www.ncbi.nlm.nih.gov/pubmed/35117067
http://dx.doi.org/10.21037/tcr.2018.11.35

Ejemplares similares